Developer docs
API playgroundTry for free, no card

Search company profiles

Stellaromics

Full company profile

uuid00009su

Namestring
Stellaromics
Legal namestring
Stellaromics, Inc.
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Stellaromics, Inc. is a privately held biotechnology company founded in 2022 and headquartered in Boston, Massachusetts, that develops and commercializes the Pyxa platform for true 3D spatial multi-omic analysis of intact, thick tissue. The platform is built on two proprietary chemistry pillars — STARmap (Spatially Resolved Transcriptomics by barcoded Amplification with Rendering) using SNAIL probe architecture, and SEDAL (Sequencing with Error-reduction by Dynamic Annealing and Ligation) — that together enable multiplexed RNA detection in tissue sections up to 100 micrometers thick, roughly an order of magnitude thicker than conventional 2D spatial biology methods. Pyxa integrates sample preparation, automated volumetric confocal imaging, and PyxaStudio data visualization into a single end-to-end workstation, with optional assays including RIBOmap (translatomics), STARmap PLUS (mRNA life cycle), and TEMPOmap (subcellular RNA kinetics). The scientific founders are Karl Deisseroth (Stanford) and Xiao Wang (Broad Institute / MIT), both widely recognized as originators of modern spatial biology methods.

The company's business model is a classic life-sciences instrument + consumables architecture: capital revenue from Pyxa instrument sales (now open for order with installations beginning in 2026), recurring revenue from proprietary reagent kits (Sample Prep, SEDAL, Buffer), 12-well plates, and custom gene panels, supplemented by fee-for-service spatial transcriptomics projects priced at approximately $60,000 for an 8-sample project. Go-to-market is enterprise field sales targeting academic research institutions (the primary segment) and biotech/pharma translational programs (a secondary segment), with strong event-driven presence at AGBT, Festival of Genomics, Neuroscience 2025, and the HCA General Meeting, and demand generation via a $60K-value Pyxa Project Grant program and an Early Access Program with limited-time introductory pricing through June 2026. The company has raised a $25 million Series A (Plaisance Capital Management lead, November 2023) and reports an additional $80 million round (Catalyst4 lead, February 2025) per company-published information, with a headcount in the 11-50 range and leadership built out for commercial scale-up including SVP Global Commercial Operations, SVP Product Development, and SVP Operations appointments in 2026.

Customer concentration is currently entirely academic across three beta installations (University of Glasgow, UC Irvine, Emory University) and reference relationships with Stanford, OHSU Vollum Institute, and Scripps Research. Operating geographies include the United States, the United Kingdom (via Glasgow), and grant eligibility extending to Australia and broader Europe. Stellaromics remains in early commercial phase: it formally launched Pyxa at AGBT in February 2026 and began first shipments in April 2026, meaning revenue generation is in its earliest stages while capital deployment is focused on commercial scale-up.

Short descriptiontext

Stellaromics develops the Pyxa platform, the first commercially available system for 3D spatial multi-omic transcriptomic analysis in intact tissue up to 100 micrometers thick. The Boston-based company sells instruments, proprietary STARmap/SEDAL reagent kits, and spatial transcriptomics services to academic research institutions and biotech/pharma customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial transcriptomics, 3D tissue imaging, spatial multi-omics, in situ sequencing, confocal imaging platform
Industry5 codes
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Spatial Biology Instruments
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pyxa Instrument Sales
TypeHardware Sales
Description

Sale of the Pyxa instrument platform - the main hardware system comprising instrument, assay kits, plates, custom panel design, PyxaStudio data visualization software, and technical support. Now commercially available with orders being taken for installation in 2026.

stellaromics.com
2Reagents and Consumables
TypeHardware Sales
Description

Ongoing sales of sample preparation kits (STARmap Sample Prep Kit for thin and thick tissue), Pyxa SEDAL Kits, Pyxa Buffer Kits, Pyxa 12-well Plates, and gene panel probes. These are recurring consumable purchases required for each experiment run on the platform.

stellaromics.com
3Custom Gene Panel Design
TypeProfessional Services
Description

Custom panel design and synthesis services for gene lists beyond the standard mouse brain panel. Allows customers to target specific genes for their research applications.

stellaromics.com
4Research Services
TypeProfessional Services
Description

Spatial transcriptomics services performed by Stellaromics on customer samples. The company performs tissue sectioning, sample preparation, imaging, and primary data analysis. Pricing indicates an 8-sample service project valued at approximately $60,000.

stellaromics.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Pyxa Project Grant - Free 8-sample service project
ModelOtherBilling cadenceOne time
Notes

Full 8-sample service project on Pyxa free of charge (value of $60,000). Includes up to eight 100 μm thick tissue samples, custom 237-gene panel design, sample preparation, imaging, and processing plus PyxaStudio access.

stellaromics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Pyxa™
Description

The first commercially available platform for multiplexed 3D spatial transcriptomics in intact tissue up to 100 micrometers thick, enabling researchers to analyze tissue architecture in three dimensions with subcellular detail

stellaromics.com
+2 more records
Core offering1 text field

Stellaromics develops and sells the Pyxa platform, an automated high-plex confocal spatial multi-omics system that generates single-cell maps of 3D gene expression in intact tissue sections up to 100 micrometers thick. The offering includes the Pyxa instrument, proprietary assay kits (STARmap Sample Prep Kit, Pyxa SEDAL Kit, Pyxa Buffer Kit), gene panels (off-the-shelf and custom), PyxaStudio visualization software, and research services performed on customer samples.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Tissue sections up to 100 micrometers thick - up to 20 times thicker than conventional platforms
+2 more records
Product overview1 text field

Stellaromics offers the Pyxa™ platform—a unified spatial multi-omics system for True 3D™ analysis of thick tissue. The platform consists of the Pyxa instrument (automated confocal imaging system), assay kits (STARmap Sample Prep Kit, Pyxa SEDAL Kit, Pyxa Buffer Kit), gene panels (Mouse Brain Pan-Neural Gene Cell Typing Panel and Custom Gene Panels), and PyxaStudio data visualization software. Supported assay technologies include STARmap (transcriptomics), RIBOmap (translatomics), STARmap PLUS (mRNA life cycle profiling), and TEMPOmap (temporal kinetics). The platform analyzes tissue sections 20-100 micrometers thick—up to 20 times thicker than conventional 2D spatial methods—preserving native cellular architecture for comprehensive 3D spatial analysis.

Product and service9 records
1Pyxa 3D Spatial Multi-Omics Platform
CategoryCore instrument platform
Description

Automated, high-plex confocal spatial platform that delivers single-cell maps of 3D gene expression in thick tissue sections up to 100 micrometers thick. End-to-end system combining sample preparation, volumetric confocal imaging, and data analysis/visualization for academic research institutions and biotech/pharma teams.

2PyxaStudio Data Visualization Software
CategoryAnalysis software
Description

Dedicated 3D data visualization software bundled with the Pyxa instrument that lets users navigate 3D tissue architecture from broad cellular organization down to subcellular transcript localization, including features for spatial distribution analysis, UMAP/spatial subselection, and bookmarking of cells and neighborhoods.

3STARmap Sample Prep Kit
CategoryReagent kit
Description

Sample preparation kit for the STARmap protocol, available in 4-well Thin (20 micron) and 4-well Thick (100 micron) formats for processing tissue on the Pyxa system.

4Pyxa SEDAL Kit
CategoryReagent kit
Description

Sequencing reagent kit using SEDAL (Sequencing with Error-reduction by Dynamic Annealing and Ligation) chemistry for decoding bases and converting sequence information into fluorescence signals; available in Thin and Thick formats.

5Pyxa Buffer Kit
CategoryReagent kit
Description

Buffer kit supporting Pyxa system processing, available in 4-well Thin and Thick formats.

6Pyxa 12-Well Plate
CategoryConsumable
Description

12-well microplate consumable compatible with the high-throughput Pyxa workflow, allowing up to 12 wells to be processed simultaneously.

7Mouse Brain Pan-Neural Gene Cell Typing Panel
CategoryGene panel
Description

Off-the-shelf gene panel for mouse brain tissue analysis, enabling targeted spatial transcriptomics profiling for neuroscience research.

8Custom Gene Panels
CategoryGene panel service
Description

Custom panel design and synthesis service that targets specific genes and tissue types beyond Stellaromics' standard panels.

9Pyxa Research Services
CategoryResearch services
Description

Fee-for-service spatial transcriptomics offering in which Stellaromics performs tissue sectioning, sample preparation, imaging, and primary data analysis on customer samples shipped to the Boston HQ. An 8-sample service project is valued at approximately $60,000.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-19
Description

Beta testing site for Pyxa platform and first installation site for Pyxa 3D spatial transcriptomics system in Europe. Professor Nigel Jamieson's lab uses the platform for tumor microenvironment research on colorectal liver metastasis and hepatocellular carcinoma.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-03
Description

First U.S. installation site for Pyxa 3D spatial transcriptomics system. Dr. Rui Chen's lab uses the platform for Human Cell Atlas initiative research on human sensory systems and eye mapping.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-03
Description

Beta testing site for Pyxa 3D spatial transcriptomics platform as part of expanded beta program. Part of broader academic collaboration for platform validation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Charitable partnership supporting Parkinson's Disease research, aligning with Stellaromics' scientific foundation in neuroscience and 'Work With Purpose' company value. The foundation's mission to cure Parkinson's Disease complements Stellaromics' spatial omics technology for brain research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Standard BioTools offers the Hyperion Imaging System for imaging mass cytometry and the SomaScan proteomics platform, both serving multi-omic tissue analysis in academic and pharma research. Comparable to Pyxa in spatial multi-omics instrumentation.

TypeBroad incumbent
Description

Bruker is a large analytical instruments manufacturer that acquired NanoString to expand into spatial biology. Comparable to Stellaromics in providing mass spectrometry and spatial omics instrumentation to research customers, though as a much broader portfolio company.

TypeDirect peer
Description

Akoya offers the PhenoCycler (formerly CODEX) platform for spatial phenomics and the PhenoImager HT for high-throughput tissue imaging. Comparable to Pyxa in instrument-based spatial biology serving translational research and immuno-oncology workflows.

TypeDirect peer
Description

Resolve Biosciences offers the Molecular Cartography platform for single-cell, subcellular spatial transcriptomics. Directly comparable as an emerging instrument-based spatial omics vendor competing for the same research dollars with single-molecule FISH-based chemistry.

TypeDirect peer
Description

Ultivue provides antibody-based spatial proteomics and transcriptomics services and reagents for tissue analysis. Comparable to Stellaromics in serving academic and pharma spatial omics needs, though focused more on proteomics than transcriptomics.

TypeDirect peer
Description

Vizgen commercializes MERFISH-based spatial transcriptomics instruments for single-cell and subcellular gene expression analysis in tissue. Directly comparable to Pyxa in product category (multiplexed spatial transcriptomics instruments) and customer base (academic and translational research).

TypeEmerging player
Description

RareCyte offers the Orion spatial biology platform for high-plex, single-cell spatial biomarker analysis in tissue. Comparable to Pyxa in instrument-based spatial multi-omics for translational and pharma research, though smaller and more niche.

TypeDirect peer
Description

NanoString's CosMx Spatial Molecular Imager and GeoMx Digital Spatial Profiler are leading spatial multi-omics platforms serving the same academic and pharma research market as Pyxa. The merger with Bruker expanded the commercial footprint, making it a more entrenched competitor.

TypeDirect peer
Description

10x Genomics is the dominant spatial biology player with Xenium (in situ) and Visium (spatial transcriptomics) platforms. Directly comparable to Stellaromics' Pyxa in target customers (academic research labs and pharma/biotech) and product category (spatial omics instruments with consumables), though currently focused on 2D workflows.

TypeEmerging player
Description

Ionpath develops MIBIscope (Multiplexed Ion Beam Imaging) for high-plex spatial proteomics in tissue. Comparable to Pyxa as an emerging instrument vendor serving translational spatial biology research with multiplexed tissue analysis capability.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stellaromics

Spatial Biology Instrumentsstellaromics.com

Stellaromics develops the Pyxa platform, the first commercially available system for 3D spatial multi-omic transcriptomic analysis in intact tissue up to 100 micrometers thick. The Boston-based company sells instruments, proprietary STARmap/SEDAL reagent kits, and spatial transcriptomics services to academic research institutions and biotech/pharma customers.

What Stellaromics does

Stellaromics, Inc. is a privately held biotechnology company founded in 2022 and headquartered in Boston, Massachusetts, that develops and commercializes the Pyxa platform for true 3D spatial multi-omic analysis of intact, thick tissue. The platform is built on two proprietary chemistry pillars — STARmap (Spatially Resolved Transcriptomics by barcoded Amplification with Rendering) using SNAIL probe architecture, and SEDAL (Sequencing with Error-reduction by Dynamic Annealing and Ligation) — that together enable multiplexed RNA detection in tissue sections up to 100 micrometers thick, roughly an order of magnitude thicker than conventional 2D spatial biology methods. Pyxa integrates sample preparation, automated volumetric confocal imaging, and PyxaStudio data visualization into a single end-to-end workstation, with optional assays including RIBOmap (translatomics), STARmap PLUS (mRNA life cycle), and TEMPOmap (subcellular RNA kinetics). The scientific founders are Karl Deisseroth (Stanford) and Xiao Wang (Broad Institute / MIT), both widely recognized as originators of modern spatial biology methods.

The company's business model is a classic life-sciences instrument + consumables architecture: capital revenue from Pyxa instrument sales (now open for order with installations beginning in 2026), recurring revenue from proprietary reagent kits (Sample Prep, SEDAL, Buffer), 12-well plates, and custom gene panels, supplemented by fee-for-service spatial transcriptomics projects priced at approximately $60,000 for an 8-sample project. Go-to-market is enterprise field sales targeting academic research institutions (the primary segment) and biotech/pharma translational programs (a secondary segment), with strong event-driven presence at AGBT, Festival of Genomics, Neuroscience 2025, and the HCA General Meeting, and demand generation via a $60K-value Pyxa Project Grant program and an Early Access Program with limited-time introductory pricing through June 2026. The company has raised a $25 million Series A (Plaisance Capital Management lead, November 2023) and reports an additional $80 million round (Catalyst4 lead, February 2025) per company-published information, with a headcount in the 11-50 range and leadership built out for commercial scale-up including SVP Global Commercial Operations, SVP Product Development, and SVP Operations appointments in 2026.

Customer concentration is currently entirely academic across three beta installations (University of Glasgow, UC Irvine, Emory University) and reference relationships with Stanford, OHSU Vollum Institute, and Scripps Research. Operating geographies include the United States, the United Kingdom (via Glasgow), and grant eligibility extending to Australia and broader Europe. Stellaromics remains in early commercial phase: it formally launched Pyxa at AGBT in February 2026 and began first shipments in April 2026, meaning revenue generation is in its earliest stages while capital deployment is focused on commercial scale-up.

Stellaromics firmographics

Firmographics
Name
Stellaromics
Legal name
Stellaromics, Inc.
Website
https://stellaromics.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
Stellaromics develops the Pyxa platform, the first commercially available system for 3D spatial multi-omic transcriptomic analysis in intact tissue up to 100 micrometers thick. The Boston-based company sells instruments, proprietary STARmap/SEDAL reagent kits, and spatial transcriptomics services to academic research institutions and biotech/pharma customers.
Ownership category
akta.pro rank

Stellaromics industry classification

Industry
Product category
Spatial Biology Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Spatial transcriptomics
  • 3D tissue imaging
  • Spatial multi-omics
  • In situ sequencing
  • Confocal imaging platform

Where Stellaromics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Stellaromics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pyxa Instrument Sales: Sale of the Pyxa instrument platform - the main hardware system comprising instrument, assay kits, plates, custom panel design, PyxaStudio data visualization software, and technical support. Now commercially available with orders being taken for installation in 2026.
  2. Reagents and Consumables: Ongoing sales of sample preparation kits (STARmap Sample Prep Kit for thin and thick tissue), Pyxa SEDAL Kits, Pyxa Buffer Kits, Pyxa 12-well Plates, and gene panel probes. These are recurring consumable purchases required for each experiment run on the platform.
  3. Custom Gene Panel Design: Custom panel design and synthesis services for gene lists beyond the standard mouse brain panel. Allows customers to target specific genes for their research applications.
  4. Research Services: Spatial transcriptomics services performed by Stellaromics on customer samples. The company performs tissue sectioning, sample preparation, imaging, and primary data analysis. Pricing indicates an 8-sample service project valued at approximately $60,000.

Pricing tiers

ModelBillingPrice
OtherOne timePyxa Project Grant - Free 8-sample service project

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Stellaromics product offering

Product offering

Core offering

Stellaromics develops and sells the Pyxa platform, an automated high-plex confocal spatial multi-omics system that generates single-cell maps of 3D gene expression in intact tissue sections up to 100 micrometers thick. The offering includes the Pyxa instrument, proprietary assay kits (STARmap Sample Prep Kit, Pyxa SEDAL Kit, Pyxa Buffer Kit), gene panels (off-the-shelf and custom), PyxaStudio visualization software, and research services performed on customer samples.

Product overview

Stellaromics offers the Pyxa™ platform—a unified spatial multi-omics system for True 3D™ analysis of thick tissue. The platform consists of the Pyxa instrument (automated confocal imaging system), assay kits (STARmap Sample Prep Kit, Pyxa SEDAL Kit, Pyxa Buffer Kit), gene panels (Mouse Brain Pan-Neural Gene Cell Typing Panel and Custom Gene Panels), and PyxaStudio data visualization software. Supported assay technologies include STARmap (transcriptomics), RIBOmap (translatomics), STARmap PLUS (mRNA life cycle profiling), and TEMPOmap (temporal kinetics). The platform analyzes tissue sections 20-100 micrometers thick—up to 20 times thicker than conventional 2D spatial methods—preserving native cellular architecture for comprehensive 3D spatial analysis.

Differentiator

Problem solved

Functional benefit

Brands

  • Pyxa™: The first commercially available platform for multiplexed 3D spatial transcriptomics in intact tissue up to 100 micrometers thick, enabling researchers to analyze tissue architecture in three dimensions with subcellular detail
  • PyxaStudio™
  • True 3D™

Products and services

  • Pyxa 3D Spatial Multi-Omics Platform Automated, high-plex confocal spatial platform that delivers single-cell maps of 3D gene expression in thick tissue sections up to 100 micrometers thick. End-to-end system combining sample preparation, volumetric confocal imaging, and data analysis/visualization for academic research institutions and biotech/pharma teams.
  • PyxaStudio Data Visualization Software Dedicated 3D data visualization software bundled with the Pyxa instrument that lets users navigate 3D tissue architecture from broad cellular organization down to subcellular transcript localization, including features for spatial distribution analysis, UMAP/spatial subselection, and bookmarking of cells and neighborhoods.
  • STARmap Sample Prep Kit Sample preparation kit for the STARmap protocol, available in 4-well Thin (20 micron) and 4-well Thick (100 micron) formats for processing tissue on the Pyxa system.
  • Pyxa SEDAL Kit Sequencing reagent kit using SEDAL (Sequencing with Error-reduction by Dynamic Annealing and Ligation) chemistry for decoding bases and converting sequence information into fluorescence signals; available in Thin and Thick formats.
  • Pyxa Buffer Kit Buffer kit supporting Pyxa system processing, available in 4-well Thin and Thick formats.
  • Pyxa 12-Well Plate 12-well microplate consumable compatible with the high-throughput Pyxa workflow, allowing up to 12 wells to be processed simultaneously.
  • Mouse Brain Pan-Neural Gene Cell Typing Panel Off-the-shelf gene panel for mouse brain tissue analysis, enabling targeted spatial transcriptomics profiling for neuroscience research.
  • Custom Gene Panels Custom panel design and synthesis service that targets specific genes and tissue types beyond Stellaromics' standard panels.
  • Pyxa Research Services Fee-for-service spatial transcriptomics offering in which Stellaromics performs tissue sectioning, sample preparation, imaging, and primary data analysis on customer samples shipped to the Boston HQ. An 8-sample service project is valued at approximately $60,000.

Quantifiable outcome

  • Tissue sections up to 100 micrometers thick - up to 20 times thicker than conventional platforms
  • +2 more outcomes

Companies that use Stellaromics

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Stellaromics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Stellaromics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • University of GlasgowcoreStrategic or Co-development Partner · 19 February 2026Beta testing site for Pyxa platform and first installation site for Pyxa 3D spatial transcriptomics system in Europe. Professor Nigel Jamieson's lab uses the platform for tumor microenvironment research on colorectal liver metastasis and hepatocellular carcinoma.
  • University of California IrvinecoreStrategic or Co-development Partner · 3 December 2025First U.S. installation site for Pyxa 3D spatial transcriptomics system. Dr. Rui Chen's lab uses the platform for Human Cell Atlas initiative research on human sensory systems and eye mapping.
  • Emory University School of MedicinecoreStrategic or Co-development Partner · 3 December 2025Beta testing site for Pyxa 3D spatial transcriptomics platform as part of expanded beta program. Part of broader academic collaboration for platform validation.
  • Michael J. Fox FoundationminorStrategic or Co-development PartnerCharitable partnership supporting Parkinson's Disease research, aligning with Stellaromics' scientific foundation in neuroscience and 'Work With Purpose' company value. The foundation's mission to cure Parkinson's Disease complements Stellaromics' spatial omics technology for brain research.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Stellaromics competitors and assessment

Company assessment

Direct peers

  • Standard BioTools (formerly Fluidigm): Standard BioTools offers the Hyperion Imaging System for imaging mass cytometry and the SomaScan proteomics platform, both serving multi-omic tissue analysis in academic and pharma research. Comparable to Pyxa in spatial multi-omics instrumentation.
  • Akoya Biosciences: Akoya offers the PhenoCycler (formerly CODEX) platform for spatial phenomics and the PhenoImager HT for high-throughput tissue imaging. Comparable to Pyxa in instrument-based spatial biology serving translational research and immuno-oncology workflows.
  • Resolve Biosciences: Resolve Biosciences offers the Molecular Cartography platform for single-cell, subcellular spatial transcriptomics. Directly comparable as an emerging instrument-based spatial omics vendor competing for the same research dollars with single-molecule FISH-based chemistry.
  • Ultivue: Ultivue provides antibody-based spatial proteomics and transcriptomics services and reagents for tissue analysis. Comparable to Stellaromics in serving academic and pharma spatial omics needs, though focused more on proteomics than transcriptomics.
  • Vizgen: Vizgen commercializes MERFISH-based spatial transcriptomics instruments for single-cell and subcellular gene expression analysis in tissue. Directly comparable to Pyxa in product category (multiplexed spatial transcriptomics instruments) and customer base (academic and translational research).
  • NanoString Technologies (now part of Bruker): NanoString's CosMx Spatial Molecular Imager and GeoMx Digital Spatial Profiler are leading spatial multi-omics platforms serving the same academic and pharma research market as Pyxa. The merger with Bruker expanded the commercial footprint, making it a more entrenched competitor.
  • 10x Genomics: 10x Genomics is the dominant spatial biology player with Xenium (in situ) and Visium (spatial transcriptomics) platforms. Directly comparable to Stellaromics' Pyxa in target customers (academic research labs and pharma/biotech) and product category (spatial omics instruments with consumables), though currently focused on 2D workflows.

Broad incumbents

  • Bruker Corporation: Bruker is a large analytical instruments manufacturer that acquired NanoString to expand into spatial biology. Comparable to Stellaromics in providing mass spectrometry and spatial omics instrumentation to research customers, though as a much broader portfolio company.

Emerging players

  • RareCyte: RareCyte offers the Orion spatial biology platform for high-plex, single-cell spatial biomarker analysis in tissue. Comparable to Pyxa in instrument-based spatial multi-omics for translational and pharma research, though smaller and more niche.
  • Ionpath (MIBIscope): Ionpath develops MIBIscope (Multiplexed Ion Beam Imaging) for high-plex spatial proteomics in tissue. Comparable to Pyxa as an emerging instrument vendor serving translational spatial biology research with multiplexed tissue analysis capability.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Stellaromics social profiles

Digital presence

Stellaromics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stellaromics leadership team

Management profile

Number of profiles

Profiles15 records

Stellaromics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stellaromics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stellaromics

What does Stellaromics do?

Stellaromics develops and sells the Pyxa platform, an automated high-plex confocal spatial multi-omics system that generates single-cell maps of 3D gene expression in intact tissue sections up to 100 micrometers thick. The offering includes the Pyxa instrument, proprietary assay kits (STARmap Sample Prep Kit, Pyxa SEDAL Kit, Pyxa Buffer Kit), gene panels (off-the-shelf and custom), PyxaStudio visualization software, and research services performed on customer samples.

Is Stellaromics a public or private company?

Stellaromics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Stellaromics founded?

Stellaromics was founded in 2022. It employs 51 to 100 people.

Where is Stellaromics based?

Stellaromics is headquartered in Boston, United States, in the North America region.

How does Stellaromics make money?

Four revenue lines are on record. Pyxa Instrument Sales are the primary driver. The others are reagents and Consumables, custom Gene Panel Design and research Services.

Who are Stellaromics's main competitors?

Direct peers on record are Standard BioTools (formerly Fluidigm), Akoya Biosciences, Resolve Biosciences, Ultivue, Vizgen, NanoString Technologies (now part of Bruker) and 10x Genomics. Bruker Corporation is listed as a broad incumbent. Emerging players are RareCyte and Ionpath (MIBIscope).

Does Stellaromics have an API?

No public API is recorded for Stellaromics.

What industry is Stellaromics in?

Stellaromics's product category is Spatial Biology Instruments. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireStellaromics Expands Pyxa® Adoption as Instruments are Installed at Leading Research Institutions Across the U.S. and EuropeStellaromics announced first commercial placements of its Pyxa 3D spatial multi-omics platform at Mount Sinai, CNAG, Karolinska Institutet, and Stanford. The systems capture subcellular detail for hundreds of targets in tissue sections up to 100 micrometers thick. The company plans to expand availability across North America, Europe, and Asia-Pacific through 2026.citybizStellaromics Adds Genomics Industry Veterans as Commercial Launch of Pyxa AcceleratesStellaromics, a Boston-based biotechnology company, has appointed Veronica Mankinen as senior vice president of global commercial operations and John Leamon, Ph.D., as senior vice president of product development as it prepares for a broader commercial rollout of its Pyxa spatial biology platform. The hires mark the company's transition from platform development into commercial scale-up in the rapidly growing spatial biology market, where Pyxa is positioned as the first platform designed for true 3D spatial analysis in intact tissue. The company has also recently expanded its board with the additions of industry veterans Stacie Weninger and Steve McPhail as it enters what management describes as a high-growth commercial phase.PR NewswireStellaromics® Appoints Veronica Mankinen as SVP Global Commercial Operations and John Leamon as SVP Product DevelopmentStellaromics announced the appointment of Veronica Mankinen as Senior Vice President of Global Commercial Operations and John Leamon, Ph.D., as Senior Vice President of Product Development to support the commercial launch of its Pyxa platform. The hires bring over 20 years of commercial leadership experience and proven track records in bringing genomic platforms to market, as the company transitions into a high-growth commercial phase. The executive additions follow recent appointments to the company's Board of Directors, strengthening Stellaromics' leadership foundation.Chemical & Engineering NewsGenomics, multiomics, and spatial biology at AGBT 2026Geneticists and instrument vendors gathered in Orlando, Florida for the AGBT 2026 conference, where the focus shifted from product launches to pricing competition among next-generation sequencing companies. Ultima Genomics launched a bulk whole-genome sequencing service for $80 per genome, while Roche's new Axelios sequencer aims to compete in the research segment but is unlikely to displace Illumina's dominance in clinical NGS for now. The conference also highlighted advances in multiomics chemistries, with vendors showcasing assays for DNA methylation, single-cell transcriptomes, and proteomes on the same instruments, alongside Stellaromics debuting a spatial transcriptomics instrument capable of 3D tissue imaging at approximately 100 micrometers depth.GenomeWebAGBT: Spatial Biology Field 'Maturing' as Updates Well-Received, if Not FlashyAt the Advances in Genome Biology and Technology (AGBT) general meeting, around half a dozen spatial biology companies announced platform updates and product launches, including Bruker showcasing two new platforms (PaintScape and CellScape) acquired from NanoString Technologies, and Stellaromics formally launching its Pyxa 3D spatial transcriptomics platform with first shipments in April. Several firms such as 10x Genomics were notably subdued at the event, while the field was described as "maturing" by industry experts who noted less flashy but practically significant developments like quality control assays. Illumina, Element Biosciences, and Singular Genomics also advanced their sequencing-based spatial methods, with Illumina claiming its spatial transcriptomics assay detected twice as many significantly expressed genes as a competitor's 5,000-gene panel.GenengnewsOmics in Orlando: A Video Report from AGBT, Day OneAt the AGBT conference in Orlando, key genomics companies announced major product launches and strategic initiatives, including Ultima launching its UG 200 series and Stellaromics debuting Pyxa as the first commercialization of a 3D spatial platform. Illumina highlighted its push into multiomics, while Rade Drmanac discussed the acquisition of Complete Genomics by Swiss Rocket AG. The article is a video recap segment featuring GEN editorial staff discussing conference highlights.The ScientistStellaromics Launches Pyxa™ at AGBT, the First Commercial Platform for 3D Spatial Multi-Omics in Intact TissueStellaromics launched Pyxa, the first commercially available platform for multiplexed 3D spatial transcriptomics in intact tissue up to 100 micrometers thick, at the Advances in Genome Biology and Technology meeting in Orlando, Florida. The platform enables researchers to analyze tissue architecture in three dimensions, capturing subcellular detail for hundreds of molecular targets simultaneously, moving beyond conventional 2D thin-section approaches. The commercial launch follows a beta program with placements at University of Glasgow, University of California Irvine, and Emory University School of Medicine, and is now available through a limited Early Access Program for research institutions and biotech/pharma teams.PR NewswireStellaromics Launches Pyxa™ at AGBT, the First Commercial Platform for 3D Spatial Multi-Omics in Intact TissueStellaromics launched Pyxa, the first commercially available platform for multiplexed 3D spatial transcriptomics in intact tissue up to 100 micrometers thick, marking a shift from 2D thin-section approaches to true 3D tissue analysis that preserves cellular architecture and microenvironments. The platform is now available through a limited Early Access Program following a beta program at three research institutions including the University of Glasgow, UC Irvine, and Emory University. The company will formally debut Pyxa at the Advances in Genome Biology and Technology meeting in Orlando, Florida.PR NewswireStellaromics Appoints Industry Veterans Stacie Weninger and Steve McPhail to Board of DirectorsStellaromics, a Boston-based company specializing in high-resolution 3D spatial multi-omics, announced the appointment of Stacie Weninger, PhD, and Steve McPhail to its Board of Directors. Dr. Weninger brings over 20 years of experience in neuroscience and venture capital as a Venture Partner at F-Prime, while McPhail adds more than three decades of executive leadership in genomics and diagnostics, including prior roles as CEO of Expression Analysis and Chief Commercial Officer at Fluidigm. The company stated these appointments are designed to support the scaling of its Pyxa™ spatial platform and expansion within the life sciences sector.PR NewswireStellaromics Expands Pyxa™ 3D Spatial Transcriptomics Beta Program with Installation at Emory University School of MedicineStellaromics announced the installation of its Pyxa™ 3D spatial multi-omics system at Emory University School of Medicine, making it the third beta program site following deployments at the University of Glasgow and UC Irvine. Dr. Hailing Shi's laboratory will use the system to research RNA regulation and neurodegenerative diseases in the human brain, focusing on spatial organization at cell-type and subcellular resolution. The Pyxa system is designed to deliver high-resolution, multiplexed 3D spatial transcriptomics in intact tissue sections up to 100 µm thick while preserving native tissue architecture.